All In Biotech

Drug Trial Radar · NCT06891885

A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

A Prospective, Open-label, Single-arm, Dose-escalation Study of the Safety and Tolerability of a Single Subretinal Uniocular Injection of Allogeneic Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Sheets (DSP-3077) in Adults With Retinitis Pigmentosa (RP)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Apr 16, 2026

Primary completion

Oct 31, 2028

Study completion Oct 31, 2032

Sponsor

Lead sponsor
Sumitomo Pharma America, Inc.Industry
Sponsor type
Industry
First posted
Mar 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Goal of this study is to evaluate the safety, tolerability, and clinical responses following single dose of DSP-3077. Study enrolls both male and female patients in 3 cohorts with each cohort defined by visual acuity (VA) criteria and dose level of DSP-3077. Each cohort will include 4 participants.

Conditions

  • Retinitis Pigmentosa

Interventions

  • DSP-3077 Retinal Sheet Cohort 1Drug

    For each participant only 1 eye will receive a low dose (\>= 0.8 to \< 2.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1

  • DSP-3077 Retinal Sheet Cohort 2Drug

    For each participant only 1 eye will receive a high dose (\>= 2.4 to \< 6.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1

  • DSP-3077 Retinal Sheet Cohort 3Drug

    For each participant only 1 eye will receive a high dose (\>= 2.4 to \< 6.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of ocular adverse events (AEs)Time frame: 60 months
  2. Incidence of ocular serious adverse events (SAEs)Time frame: 60 months
  3. Incidence of ocular adverse events (AEs) leading to discontinuationTime frame: 60 months
  4. Incidence of adverse events (AEs)Time frame: 60 months
  5. Incidence of serious adverse events (SAEs)Time frame: 60 months
  6. Incidence of adverse events (AEs) leading to discontinuationTime frame: 60 months
  7. Incidence of adverse events (AEs) leading to deathTime frame: 60 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Massachusetts Eye and Ear

    Boston, Massachusetts · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.